LTI-01 is currently in a Phase 2, randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions.

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a serious complication of pneumonia, and LTI-03 to treat idiopathic pulmonary fibrosis.

Proceeds to fund completion of Phase II Clinical Trial for drug candidate LTI-01 in Loculated Pleural Effusions and Phase I Clinical Trial for Idiopathic Pulmonary Fibrosis (IPF) candidate LTI-03 ...

AUSTIN, Texas, March 14, 2017 /PRNewswire/ -- Lung Therapeutics, Inc., a clinical stage pharmaceutical company focused on niche, orphan drug indic ...

Lung Therapeutics announced that it received Orphan Drug Designation for LTI-01, an injectable designed for the treatment of loculated pleural effusion. Lung Therapeutics, a pharmaceutical company ...

Aileron Therapeutics, Inc. Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be ...